NASDAQ-traded clinical biotechnology company focused on developing treatments for rare and common neurodegenerative diseases.- Created, implemented and managed a comprehensive and proactive investor and corporate communications program following Vigil’s IPO to effectively deliver corporate messages and enhance awareness among key audiences, including investors, analysts, media, patients and employees.- Implemented and led quarterly communications strategy planning meetings to ensure cross-functional alignment on key corporate milestones and the timing of public disclosures.

NASDAQ-traded biotechnology company specializing in discovering and developing antibody-drug conjugate (ADC) therapies to treat patients fighting cancer.- Developed, implemented and managed a comprehensive investor relations program that enhanced current shareholder and sell-side analyst engagement and increased new long-only institutional ownership and analyst coverage.- Worked closely with the leadership team and across the organization to identify, plan, and leverage key newsflow to demonstrate the achievement of milestones and enhance shareholder value.- Partnered with a public relations consultant to implement patient advocacy activities, identify media targets and opportunities for engagement and develop and implement a social media plan to improve corporate visibility.

NASDAQ-traded biotechnology company specializing in the characterization and engineering of complex mixture drugs, including generic versions of complex drugs, biosimilars and novel drugs for autoimmune indications. Acquired by Johnson & Johnson in October 2020.- Developed, implemented and managed a strategic investor relations and corporate communications program that successfully increased analyst coverage and brought new, long-term investors into the stock as the Company transitioned from a specialty pharmaceuticals company to a biotechnology company.

Established in 1970, the Boston Chapter of the National Investor Relations Institute (NIRI Boston) is one of the largest and oldest chapters of NIRI, a professional association of investor relations practitioners, corporate officers and consultants responsible for strategic communication among corporate management, the investing public and the financial community. NIRI Boston is dedicated to the professional advancement of its members by supporting the Investor Relations function and fostering a greater understanding of effective and ethical investor relations practices.

NASDAQ-traded industrial biotechnology company focused on developing and commercializing high-performance enzymes for use in industrial processes. Acquired by BASF Corporation in October 2013.- Developed, implemented and managed an integrated investor relations and corporate communications program.- Successfully led various public and investor relations events to enhance Company visibility, including analyst days, roadshows, annual shareholder meetings, and investor and industry conferences.